Interim Results, page-30

Primarily the current trial program is to prove safety in humans.
There is an efficacy element.
We are also trying to confirm that the nanoparticles can effectively identify spread of cancer from the primary site to the lymph nodes.
In addition to that we are collaborating with Siemens to establish if our nanoparticles can be effectively used as an agent in existing MRI machines.
Overall a pretty big deal on the journey to market. 
Success in these trials will in all likelihood be a massive game changer and bring interest from large imaging players beyond just Siemens.
The potential upside is huge IMO.
DYOR.